linjc16/ctgov huggingface dataset:
Proteomics Research of Osteosarcoma

Study Overview
=================
Brief Summary
-----------------
Retrospectively collected 400 cases of clinical data and pathological paraffin specimens of osteosarcoma, chondrosarcoma (control) and endogenous chondroma (control) in our hospital from 2008 to 2014, combined with high-pressure cycle-satellite scanning mass spectrometry (PCT-SWATH) Molecular typing of osteosarcoma and prediction of targeted therapy, the establishment of a new molecular classification based on proteomics for osteosarcoma to predict the chemotherapy response and recurrence risk of osteosarcoma. Clinical osteosarcoma patients include as many types as possible: pre-chemotherapy, post-chemotherapy, recurrence, and metastasis. The study did not involve vulnerable groups, and it was taken as a postoperative wax specimen for patients, which had no health, life and other effects on patients. Study application exemption from informed consent.

Official Title
-----------------
Establishment of New Molecular Prototyping Based on Proteomics for Predicting Osteosarcoma Chemotherapy Response and Risk of Recurrence

Conditions
-----------------
Osteosarcoma, Proteomics

Intervention / Treatment
-----------------
* Drug: Chemotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all osteosarcoma patients in our hospital received Methotrexate+Doxorubicin+Cisplatin protocol chemotherapy Exclusion Criteria: non-chemotherapy patients bio-specimen not completed
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| osteosarcoma<br> | Drug: Chemotherapy<br>* all osteosarcoma patients will give regular chemotherapy for osteosarcoma, the protocol is the same as Methotrexate+Doxorubicin+Cisplatin.<br>|
| chondrosarcoma<br> | |
| enchondroma<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| proteomics changes | Study of changes in proteomes in tumor cells by high-throughput proteomics analysis | 2 years |
Indications and Outcomes in Kidney-ureteral Pediatric Lithiasis: Experience of Parma

Study Overview
=================
Brief Summary
-----------------
Incidence of paediatric urolithiasis is increasing in Europe and North America. Nowadays the management of stone disease is a common practice in not endemic country. The surgical's treatment is based on similar techniques as for adults. In the last years due to miniaturization of endoscopic instruments endourology has become the best approach to treat urinary stones in children. The investigators have retrospectively reviewed experience from 01/01/2000 to 28/02/2019 in children ≤ 16 years old affected by urinary stones who underwent rigid and flexible ureterorenoscopy and pecutaneous nephrolitotripsy procedures and recorded clinical data, overall success rate and complication.

Official Title
-----------------
Indications and Outcomes in Kidney-ureteral Pediatric Lithiasis: Experience of Parma

Conditions
-----------------
Pediatric ALL, Stone, Urinary

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 0-17 yrs old, urinary stones (kidney, ureteral, not bladder), with or without malformations or metabolic diseases Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| stone free rate | no stones or residual fragment < 4 mm | immediately | 
| stone free rate | no stones or residual fragment < 4 mm | 3 months follow up | 
| complication rate | clavien-dindo classification | immediately | 
| complication rate | clavien-dindo classification | 3 months follow up |
Correlation of the Dural Sac Dimension With the Spread of Spinal Anesthesia

Study Overview
=================
Brief Summary
-----------------
Cerebrospinal fluid volume is an important factor that influences peak block height and regression of sensory and motor blockade. The aim of this study is to evaluate the effect of dural sac dimension on the spread of spinal anesthesia in elderly patient using ultrasound.

Official Title
-----------------
Correlation of the Dural Sac Dimension With the Spread of Spinal Anesthesia in Elderly Patients

Conditions
-----------------
Elderly Patients

Intervention / Treatment
-----------------
* Other: Ultrasound assessment of dural sac dimension


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are scheduled for elective surgery under spinal anesthesia Exclusion Criteria: Known anatomical abnormality or pathology in the spine History of lumbar spinal surgery or compression fracture Height less than 150 cm

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Ultrasound assessment of dural sac dimension|Dural sac dimension is assessed using ultrasonography in the lateral decubitus position for spinal anesthesia.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between the dural sac dimension and spinal anesthesia spread (peak sensory block) | The dural sac dimension is assessed before spinal anesthesia. After spinal anesthesia, the sensory and motor level are evaluated. Then, the correlation between the dural sac dimension and spinal anesthesia blockade is assessed. | At 30 minutes after the induction of spinal anesthesia | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between the dural sac dimension and duration of spinal anesthesia | The sensory and motor regression are assessed. Then, the correlation between the dural sac dimension and the duration of spinal blockade is assessed. | At 30 minutes after the end of surgery | 
| Correlation between the dural sac dimension and body mass index | Correlation between the dural sac dimension and body mass index is assessed. | 5 minutes before spinal anesthesia | 
| Correlation between the dural sac dimension and waist circumference | Correlation between the dural sac dimension and waist circumference is assessed. | 5 minutes before spinal anesthesia | 
| Correlation between the dural sac dimension and age | Correlation between the dural sac dimension and age is assessed. | 5 minutes before spinal anesthesia |
Influence of Opioid Analgesia on Circulating Tumor Cells in Open Colorectal Cancer Surgery

Study Overview
=================
Brief Summary
-----------------
To compare the effects of three types of perioperative analgesia on the number of circulating tumor cells following radical colorectal cancer surgery. To find correlations with other perioperative factors and clinical/pathological disease characteristics.

Official Title
-----------------
Influence of Peri-operative Opioid Analgesia on Circulating Tumor Cells in Patients Undergoing Open Colorectal Cancer Surgery - Multi-center, Randomized Clinical Trial

Conditions
-----------------
Colorectal Cancer, Circulating Tumor Cell

Intervention / Treatment
-----------------
* Drug: Morphine
* Drug: Piritramid
* Drug: Epidural


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing open radical surgery for colorectal cancer age over 18 years signed informed consent Exclusion Criteria: intolerance of the study drugs history of CRC surgery neoadjuvant therapy contraindications to epidural analgesia other malignancy not in permanent remission chronic opioid medication or opioid administration within 7 days preoperatively immunosuppressive or corticosteroid therapy surgery within 30 days preoperatively (except minor) chronic or acute infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Morphine<br>Morphine-based perioperative analgesia | Drug: Morphine<br>* Morphine intravenous<br>|
| Active Comparator: Piritramid<br>Piritramid-based perioperative analgesia | Drug: Piritramid<br>* Piritramid intravenous<br>|
| Active Comparator: Epidural<br>Perioperative epidural analgesia containing an opioid | Drug: Epidural<br>* Perioperative epidural analgesia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in number of circulating tumor cells prior to surgery to 2 - 4 weeks after surgery | Baseline number of circulating tumor cells will be recorded prior to surgery in a venous blood sample. Number of circulating tumor cells will be measured 2 - 4 weeks after surgery in a venous blood sample. These two values will be compared. | 1 - 3 days before surgery to 4 weeks after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain assessment | Pain intensity assessed using Numerical Rating Scale (0-10) | 3 days postoperatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Perioperative analgesia, Colorectal Cancer, Circulating Tumor Cell
Skin Flap Visible Light Spectroscopy (VLS) Oximetry for Monitoring Free-Flap Ischemia During Breast Reconstruction and Recovery

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to understand the relevance of tissue oximetry measures of tissue flaps during surgery and during recovery, and to determine if T-Stat is a reliable and early method of detecting compromised flaps.

Detailed Description
-----------------
The tissue saturation of free flaps will be measured before, during, and after surgery and during recovery.

Official Title
-----------------
Skin Flap Visible Light Spectroscopy (VLS) Oximetry for Monitoring Free-Flap Ischemia During Breast Reconstruction and Recovery

Conditions
-----------------
Ischemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Under surgical breast reconstruction Informed consent Exclusion Criteria: Failure to give consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Flap Failure and Compromise by Tissue Saturation Values (Efficacy) |  | 72 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oximetric Diagnosis compared to Clinical Diagnosis, Doppler |  | 72 hours | 
| Device Safety Measures (safety) |  | 72 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Free Flap, Surgery, Ischemia, Outcome, Reconstructive Plastic Surgery, Monitoring
Efficacy and Safety of Dapagliflozin in Children With Proteinuria

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to investigate the antiproteinuric effect of Dapagliflozin in children with proteinuria.

Official Title
-----------------
Efficacy and Safety of Dapagliflozin in Non-diabetic Children With Proteinuria

Conditions
-----------------
Proteinuria

Intervention / Treatment
-----------------
* Drug: Dapagliflozin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 6 years to 18 years; Urinary protein excretion > 0.2g in a 24-hr urine collection; eGFR≥60 ml/min/1.73m2; No history of diabetes; On stable doses of ACE inhibitors or angiotensin receptor blockers (ARBs) for > 1 month; Exclusion Criteria: Receiving immunosuppressive therapy within three months prior to enrolment. Blood pressure less than 5th percentile of the same gender, age, and height - Leukocyte and/or nitrite positive urinalysis that is untreated; History of organ transplantation, cancer, liver disease; Evidence of hepatic disease as determined by any one of the following: ALT or AST values exceeding 3x ULN at the screening visit; History of noncompliance to medical regimens or unwillingness to comply with the study protocol.

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dapagliflozin treatment<br> | Drug: Dapagliflozin<br>* Dapagliflozin will be given 5mg per day (weight≤30kg) or 10mg per day (weight>30kg), for 12 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The change in 24-hr proteinuria after a 4 weeks treatment with dapagliflozin | Urine will be collected for 24 hours and total urinary protein will be detected | From baseline to weeks 4 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The change in 24-hr proteinuria after a 12 weeks treatment with dapagliflozin | Urine will be collected for 24 hours and total urinary protein will be detected | From baseline to weeks 12 | 
| The change in eGFR after a 12 weeks treatment with dapagliflozin | eGFR are repeated measurement data and will be evaluated by Schwartz formula（k*height（cm)/creatinine(umol/L), k=36.5） | Measured at baseline, weeks 4, weeks 8, weeks 12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
proteinuria, SGLT2i
Sleep Actigraphy in Postural Tachycardia Syndrome (POTS)

Study Overview
=================
Brief Summary
-----------------
We propose to use actigraphy (measured by activity watches) as a tool to quantify sleep disturbances in patients with orthostatic intolerance compared with healthy control subjects. In this pilot study, we will test the null hypothesis (Ho) that there are no differences in the sleep quality between patients with orthostatic intolerance and healthy control subjects.

Official Title
-----------------
Assessment of Objective Sleep Disturbances in Orthostatic Intolerance Using Actigraphy

Conditions
-----------------
Postural Tachycardia Syndrome, Orthostatic Intolerance, Sleep Disorders

Intervention / Treatment
-----------------
* Device: Actigraphy Watch (motion sensors) with light sensors - ActiWatch from Minimitter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with orthostatic intolerance by the Vanderbilt Autonomic Dysfunction Center Control subjects will be free of orthostatic intolerance and other major medical problems, free of medications during the study Age between 18-65 years Male and female subjects are eligible. Able and willing to provide informed consent Exclusion Criteria: Overt cause for postural tachycardia (such as acute dehydration) Self-report of pregnancy Inability to give, or withdrawal of, informed consent Other factors which in the investigator's opinion would prevent the subject from completing the protocol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Patients meeting the diagnostic criteria for the Postural Tachycardia Syndrome, a form of Orthostatic Intolerance | Device: Actigraphy Watch (motion sensors) with light sensors - ActiWatch from Minimitter<br>* Watch to be worn on wrist for 7 days (except in water) that will measure activity/movement.<br>* Other names: ActiWatch from Minimitter;|
| 2<br>Healthy control subjects who do not meet the criteria for the Postural Tachycardia Syndrome | Device: Actigraphy Watch (motion sensors) with light sensors - ActiWatch from Minimitter<br>* Watch to be worn on wrist for 7 days (except in water) that will measure activity/movement.<br>* Other names: ActiWatch from Minimitter;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sleep Latency |  | 1 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sleep Efficiency |  | 1 week | 
| Wake After Sleep Onset |  | 1 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sleep, Orthostatic tachycardia, POTS
Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease

Study Overview
=================
Brief Summary
-----------------
This research study is being done because patients with a history of chest radiation treatment for Hodgkin's disease have been shown to be at increased risk for developing lung cancer a number of years out from treatment. The risk appears to be further increased among patients with a smoking history. Currently, the practice is to recommend annual low-dose chest CT scans in survivors of Hodgkin's disease who have received prior chest radiation treatment and who have at least a moderate smoking history. In this study, the CT scans will be read and interpreted by the study radiologist, and the results recorded in a consistent manner.

Detailed Description
-----------------
- Participants will undergo a chest computed tomography (CT) scan once a year for a 3-year period.

Official Title
-----------------
Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Procedure: chest computed tomography scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 5 years or longer from initial Hodgkin's disease diagnosis Current age 18 or older Received mediastinal irradiation and/or alkylating-agent based chemotherapy Smoking history of 10-pack years or more, or current smoker Pre-approval from the participant's insurance company for the CT study Exclusion Criteria: Patients with a history of lung cancer Currently receiving treatment for another cancer diagnosis Known diagnosis of any metastatic cancer Pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Interventional Model Description: Single arm study of low-dose Chest CT screening for long-term Hodgkin lymphoma survivors
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Low-dose Chest CT screening<br>Annual low-dose Chest CT screening | Procedure: chest computed tomography scan<br>* Once a year for three years<br>* Other names: CT scan;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To Prospectively Collect Data on Chest CT Screening for Patients at Increase Lung-cancer Risk After Hodgkin's Disease. | In this study, patients will under annual low-dose chest CT screening. The total number of lung cancer detected through the screening will be recorded | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hodgkin's disease, CT scan
Alkaline Phosphatase Level in Pregnancy and Its Association With Birth Weight

Study Overview
=================
Brief Summary
-----------------
Alkaline phosphatase is known to be produced by syncytiotrophoblasts in the placenta and its levels are normally increased in pregnancy. Therefore, it would be reasonable to hypothesize that alkaline phosphatase would be low to low normal in cases of low birth weight / intrauterine growth restriction (IUGR)/ placental insufficiency.

Detailed Description
-----------------
The purpose of this study will be to determine if alkaline phosphatase can be used as a predictor for suboptimal fetal growth, placental insufficiency and low birth weight (birth weight less than 2500 grams). It will also help determine if alkaline phosphatase can be used as a screening tool for low birth weight/IUGR at the time of the 24 to 28 week labs.

Official Title
-----------------
Alkaline Phosphatase Level in Pregnancy and Its Association With Birth Weight

Conditions
-----------------
Low Birth Weight Infants

Intervention / Treatment
-----------------
* Diagnostic Test: Testing of Alkaline Phosphatase Levels


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Patients enrolled between 24w0d and 28w6d weeks gestational age will be included. The blood specimen of the patients enrolled will be held until delivery. Exclusion Criteria: Multiple gestations Known congenital malformations (any, except Pyelectasis) Chronic hypertension Inflammatory bowel disease (IBD) Gall bladder disease Active bone disease (ie, skeletal dysplasia, healing fracture) Active liver disease (ie, hepatitis, cholestasis, cholelithiasis (gallstones)) Pre-existing type 1 and 2 Diabetes Early-onset IUGR

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pregnant women at 24-28 weeks gestation<br>Pregnant women, aged 18 and older, who are seen for their prenatal care and who are between 24w0d and 28w6d weeks gestation.Their alkaline phosphatase levels will be tested in this study. | Diagnostic Test: Testing of Alkaline Phosphatase Levels<br>* Testing of alkaline phosphatase levels at the time of the 24w0d to 28w6d week labs.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Birth Weight at Delivery | Birth Weight at Delivery | At Delivery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Alkaline Phosphatase, Pregnancy, Suboptimal fetal growth, Placental insufficiency, Low birth weight, IUGR